Improvements of survival in nine phase II clinical studies with different types of cancer upon anti-tumor vaccination with an autologous tumor cell vaccine modified by virus infection to introduce danger signals.
Schirrmaker
Volker
V
German Cancer Research Center, Division of Cellular Immunology, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
D000818:Animals; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology / Q000401:mortality* / Q000628:therapy*; D009522:Newcastle disease virus / Q000235:genetics; D016896:Treatment Outcome; D014611:Vaccination; D014765:Viral Vaccines
D019496:Cancer Vaccines; D014765:Viral Vaccines